Outlook Therapeutics Inc. will hold its 2026 Annual Meeting of Stockholders on March 10, 2026. During the meeting, stockholders will vote on the election of three directors, the ratification of the selection of KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending September 30, 2026, and a non-binding advisory vote on the compensation of Outlook Therapeutics’ named executive officers.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-002406), on January 26, 2026, and is solely responsible for the information contained therein.